NICE recommends drug to prevent episodes of hepatic encephalopathy

Rifaximin (Targaxan) has been accepted by NICE for preventing recurrent hepatic encephalopathy.

Hepatic encephalopathy is a complication of cirrhosis. | SCIENCE PHOTO LIBRARY
Hepatic encephalopathy is a complication of cirrhosis. | SCIENCE PHOTO LIBRARY

Rifaximin is recommended by NICE as an option for reducing recurrent episodes of overt hepatic encephalopathy in adults.

Further information
NICE technology appraisal TA337

Rifaximin is a semi-synthetic derivative of the antibiotic rifamycin. It is thought to delay episodes of hepatic encephalopathy by reducing intestinal absorption and production of ammonia. High levels of ammonia and other toxins are believed to cause the neurocognitive symptoms of hepatic encephalopathy.

The SPC notes that over 90% of patients in the pivotal study of rifaximin were also taking lactulose.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases